文献速递皮肤肿瘤

母细胞性浆细胞样树突状细胞肿瘤的临床多样性与治疗:一项回顾性多中心研究

Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-03-10

该多中心回顾性研究收集了1999年5月至2018年3月德国-瑞士-奥地利皮肤淋巴瘤工作组10个中心的37例BPDCN病例,发现近90%患者有皮肤外系统受累,皮损表现多样,化疗/放疗后全部复发死亡,而造血干细胞移植后死亡率仅33.33%,中位生存60.5个月。

要点

  • BPDCN常以皮肤为首发表现,但近90%伴骨髓、淋巴结或外周血受累。
  • 皮损呈结节(>2/3)、瘀斑样(1/3)、斑丘疹(约1/6)等多种形态。
  • 化疗/放疗后虽初期有效但均复发死亡,HSCT可显著改善生存。

核心结论

  • BPDCN皮肤表现具有临床多样性,引入HSCT后观察到生存改善。

研究设计与样本

  • 多中心回顾性研究,纳入德国-瑞士-奥地利皮肤淋巴瘤工作组10个二级中心1999年5月至2018年3月的37例BPDCN病例。

主要发现

  • 近90%患者除皮肤受累外还有系统表现(骨髓、淋巴结、外周血)。
  • 皮损类型:结节性超过2/3,瘀斑样约1/3,斑丘疹约1/6。
  • 22例接受化疗和/或放疗者虽初期有效但最终均复发并死于疾病进展。

关键数值与推荐

  • HSCT患者死亡率33.33%,中位生存时间60.5个月。

临床怎么用

  • 对皮肤结节、瘀斑样或斑丘疹伴系统受累者应警惕BPDCN并及时评估。
  • 治疗上应考虑造血干细胞移植以改善长期生存。

局限性

  • 回顾性研究,样本量较小(37例),来自特定地区工作组中心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive type of haematologic precursor malignancy primarily often manifesting in the skin. We sought to provide a thorough clinical characterization and report our experience on therapeutic approaches to BPDCN. METHODS: In the present multicentric retrospective study, we collected all BPDCN cases occurring between 05/1999 and 03/2018 in 10 secondary care centres of the German-Swiss-Austrian cutaneous lymphoma working group. RESULTS: A total of 37 BPDCN cases were identified and included. Almost 90% of the patients had systemic manifestations (bone marrow, lymph nodes, peripheral blood) in addition to skin involvement. The latter presented with various types of cutaneous lesions: nodular (in more than 2/3) and bruise-like (in 1/3) skin lesions, but also maculopapular exanthema (in circa 1/6). Therapeutically, 22 patients received diverse combinations of chemotherapeutic regimens and/or radiotherapy. Despite initial responses, all of them ultimately relapsed and died from progressive disease. Eleven patients underwent haematopoietic stem cell transplantation (HSCT; autologous HSCT n = 3, allo-HSCT n = 8). The mortality rate among HSCT patients was only 33.33% with a median survival time of 60.5 months. CONCLUSION: Our study demonstrates the clinical diversity of cutaneous BPDCN manifestations and the positive development observed after the introduction of HSCT.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Brüggen MC, Valencak J, Stranzenbach R, et al. Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre study. J Eur Acad Dermatol Venereol. 2020. PMID: 31955469. doi:10.1111/jdv.16215

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。